Intranasal basic fibroblast growth factor attenuates endoplasmic reticulum stress and brain injury in neonatal hypoxic-ischaemic injury

Zhenlang Lin1,2*, Yingying Hu2*, Zhouguang Wang3*, Shulin Pan2, Hao Zhang2, Libing Ye3, Hongyu Zhang3, Mingchu Fang2, Huai Jiang2, Junming Ye4, Jian Xiao3, Li Liu1

1Department of Neonatology, The First Affiliated Hospital of Xi’an Jiaotong University, Xi’an 710061, Shaanxi, China; 2Department of Neonatology, The Second Affiliated Hospital and Yuying Children’s Hospital, Wenzhou Medical University, Wenzhou 325027, Zhejiang, China; 3Molecular Pharmacology Research Center, School of Pharmacy, Wenzhou Medical University, Wenzhou 325035, Zhejiang, China; 4Department of Anesthesia, The First Affiliated Hospital, Gannan Medical College, Ganzhou, 341000, China. *Equal contributors.

Received October 4, 2016; Accepted January 30, 2017; Epub February 15, 2017; Published February 28, 2017

Abstract: Brain injury secondary to birth asphyxia is the major cause of death and long-term disability in newborns. Intranasal drug administration enables agents to bypass the blood-brain barrier (BBB) and enter the brain directly. In this study, we determined whether intranasal basic fibroblast growth factor (bFGF) could exert neuroprotective effects in neonatal rats after hypoxic-ischaemic (HI) brain injury and assessed whether attenuation of endoplasmic reticulum (ER) stress was associated with these neuroprotective effects. Rats were subjected to HI brain injury via unilateral carotid artery ligation followed by 2.5 h of hypoxia and then treated with intranasal bFGF or vehicle immediately after HI injury. We found that the unfolded protein response (UPR) was strongly activated after HI injury and that bFGF significantly reduced the levels of the ER stress signalling proteins GRP78 and PDI. bFGF also decreased brain infarction volumes and conferred long-term neuroprotective effects against brain atrophy and neuron loss after HI brain injury. Taken together, our results suggest that intranasal bFGF provides neuroprotection function partly by inhibiting HI injury-induced ER stress. bFGF may have potential as a therapy for human neonates after birth asphyxia.

Keywords: bFGF, hypoxic-ischaemia brain injury, ER stress, neuroprotection

Introduction

An alarming rise in neonates suffer from birth asphyxia has created a substantial health and economic burden worldwide [1]. An estimated 4 to 9 million new-borns are diagnosed as asphyxia each year, along with approximately 1.2 million deaths and the same number of infants with severe disabilities [2, 3]. Hypoxic-ischemia (HI) encephalopathy is one of the leading causes of neurological disabilities. Several long-term neurological or cognitive disabilities related to HI encephalopathy include cerebral palsy, epilepsy and mental retardation [4-6]. However, an effective therapeutic approach mitigating HI encephalopathy, especially in the developing countries, has not been established.

The endoplasmic reticulum (ER) is an intracellular organelle, characterized a network of membrane-enclosed sacs and tubules, found in eukaryotic cells. Both physiological and pathological functions of ER have been studied extensively. While ER is responsible for production of proteins and lipids, ER stress induces activation of the unfolded protein response (UPR), which resets ER homeostasis by enhancing protein folding, reducing protein translation and increasing ER associated degradation [7]. Several physiological triggers, such as HI [8], depletion of ER Ca2+ stores [9], free radicals [10], and elevated unfolded or misfolded protein levels [11], have been identified to activate the UPR. It is important to understand that the UPR is triggered to allow the cells to restore homeostasis by regulating cell growth, differen-
bFGF attenuates neonatal hypoxic-ischaemic brain injury

tiation and apoptosis. Previous studies have demonstrated that ER stress-induced injury is associated with activation of glucose-regulated protein 78 (GRP78), protein disulfide isomerase (PDI), EBP homologous transcription factor (CHOP), X-box binding protein 1 (XBP-1), and transcription factor-6 (ATF-6) [12-15]. If the ER stress is chronically prolonged and the adaptive mechanism fails, tissue injury manifested by cellular dysfunction and cell death often occurs during HI [16, 17]. Thus, it has been hypothesized that the ER stress initiates extensive neuronal cell death and malfunction, and this pathological mechanism may contribute to the neonatal HI injury.

Basic fibroblast growth factor (bFGF or FGF-2) is a member belongs to the fibroblast growth factor family, which is implicated in a diverse biological function, including cellular proliferation, differentiation and survival during development [18-20]. Several lines of evidence had highlighted that bFGF played an essential role in neurotropic activities, including neural stem cell maintenance and proliferation, in the subventricular zone of neonatal rat brains [21]. Furthermore, neural stem/progenitor cell transplantation improved brain function after cerebral ischaemic injury, and such protective effect was further enhanced by bFGF, in which increased NSCs/neural progenitor cell proliferation and functional recovery were observed in transplanted rats [22]. Although the beneficial effect has been well documented, the molecular mechanisms underlying the therapeutic effects of bFGF in neonatal HI recovery are still undefined. In this study, we sought to examine the molecular mechanisms by which bFGF mitigated ER stress-induced brain injury in neonatal rats.

Materials and methods

Reagents and antibodies

Dulbecco’s modified Eagle medium (DMEM) and foetal bovine serum (FBS) were purchased from Invitrogen (Invitrogen, Carlsbad, CA). Recombinant human basic fibroblast growth factor (bFGF) was purchased from Key Laboratory of Biotechnology and Pharmaceutical Engineering, Zhejiang, China. Hyaluronidase and 2,3,5-triphenyltetrazolium chloride (TTC) (dissolved in PBS) were obtained from Sigma-Aldrich (St. Louis, MO, USA). Primary antibodies against ATF6, GRP78, PDI, XBP-1, ATF4, caspase12 and caspase3 were purchased from Abcam (Cambridge, MA, USA). Anti-actin, CHOP, microtubuli associated protein 2 (MAP-2) and myelin basic protein (MBP) were acquired from Santa Cruz Biotechnology (Santa Cruz, CA, USA). The appropriate secondary antibodies were obtained from Santa Cruz Biotechnology or Abcam.

Animals and surgical procedures

Sprague-Dawley (SD) rats were purchased from the Animal Centre of the Chinese Academy of Sciences. Adult rats were crossed to give newborns for subsequent studies. All animal work was performed under the animal use and care protocol conformed to the Guide for the Care and Use of Laboratory Animals from the National Institutes of Health and Wenzhou Medical University. The day of delivery was considered day 0 for the pups. Neonatal rats were maintained in an environment of constant temperature and regular 12-h day, 12-h night cycles with access to food and water. The model used in this study was adapted from the study by Vannucci R.C. et al [23]. On postnatal day 7 (P7), the pups underwent unilateral ligation of the left common carotid artery via a midline neck incision after anaesthesia with diethyl ether. After ligation, the wound was sutured, and they were allowed to recover for 2 h before exposed to humidified nitrogen-oxygen mixture (92% and 8%, respectively, delivered at 3-4 L/min) for 2.5 h. The chamber was partially submerged in a 37°C water bath to maintain a constant thermal environment. Sham animals received anaesthesia, and their common carotid arteries were exposed but were not subjected to ligation. After the neonatal HI model was established, pups were administered bFGF or saline and returned to their dams for subsequent experiments.

Intranasal administration

Neonatal rats were randomly assigned to the treatment group receiving intranasal bFGF or the sham group receiving saline. bFGF was prepared by dissolving in 0.9% saline solution (100 μg/ml) and stored at -20°C for future use. bFGF or saline was administered as drops to the nostrils (100 ng/g) immediately after HI injury. Before bFGF administration, each neonatal rat was given hyaluronidase (Sigma-Aldrich) to
bFGF attenuates neonatal hypoxic-ischaemic brain injury

increase the permeability of bFGF to the CNS. Each rat was held ventral-side up, and a small-modified 27-French catheter was inserted into either nare. bFGF or saline was slowly administered, and the rats were held for 1-2 min to ensure absorption. Then, bFGF or saline was administered twice a day until postnatal day 14 (P14).

_cell culture_

PC12 cells were purchased from the Type Culture Collection of the Chinese Academy of Sciences, Shanghai, China. Cells were grown in DMEM supplemented with 10% FBS and 1% antibiotics and then incubated in a humidified atmosphere containing 5% CO₂ at 37°C. PC12 cells were pretreated with bFGF (50 μg/ml) for 2 h. All experiments were performed in triplicate.

_immunohistochemistry and antibodies_

Freshly cut, free-floating brain sections (5 μm thick) from P14 rats were prepared. Sections were incubated with 3% H₂O₂ in methanol for 10 min, followed by blocking with 5% BSA in PBS at 37°C for 30 min [24, 25] and incubating with primary antibodies (1:200 for MAP-2 or 1:200 for MBP) at 4°C overnight. Sections were then washed with PBS and incubated with an appropriate secondary antibody donkey anti-rabbit (1:1000; Abcam) or donkey anti-goat (1:300; Santa Cruz, CA, USA) at 37°C for 1 h [26]. Nuclei were counterstained with 4', 6-diamidino-2-phenylindole (DAPI) [27]. The images of MAP-2 and MBP were visualized using a Nikon ECLIPSE Ti microscope (Nikon, Tokyo, Japan). The extent of tissue damage was determined by calculating the amount of surviving tissue in each section. Briefly, brain damage was analyzed using the ImageJ software (http://imagej.nih.gov/ij/) by outlining both hemispheres on full section images. The ipsilateral MAP-2 area loss was measured as [1-(area ipsilateral MAP-2 staining/area contralateral MAP-2 staining)] ×100. The MBP area was determined as same as the calculation method of the MAP-2 area loss.

_measurement of infarct ratio_

TTC staining was used to measure infarct volumes as previously described [28]. In brief, animals were perfused with saline under deep anaesthesia at 24 h after HI brain injury. Brains were isolated, sectioned into 2 mm slices, and then immersed in 1% TTC solution at 37°C for 15-20 min, followed by 4% paraformaldehyde. Images were captured, and infarct volumes were analyzed using the ImageJ software (http://imagej.nih.gov/ij/) by outlining both hemispheres on full section images.

_Haematoxylin-eosin and Nissl staining_

For HE and Nissl staining, brain sections from the P14 rats were hydrated using a Haematoxylin-eosin (HE) Staining Kit (Beyotime) or Nissl staining solution (Beyotime) for 10 min at room temperature. After being rinsed with double distilled water, sections were dehydrated and mounted with Mowiol. Images of the cortex and CA1 area of the hippocampus were captured accordingly. Quantitation was performed by counting the number of normal neurons in five randomly chosen fields within each slide at 400× magnification using a Nikon ECLIPSE Ti microscope. The average cell density was calculated as the ratio of the overall normal neurons number to the total area of the chosen field.

_Apoptosis assay_

For in vivo studies, DNA fragmentation was detected using an In Situ Cell Death Detection Kit (Roche, South San Francisco, CA, USA). According to the standard protocol, brain sections from the P14 rats were deparaffinized and rehydrated, which followed by an incubation with proteinase K (20 μg/ml) at 37°C for 15 min. For in vitro studies, cells were incubated in 3% H₂O₂ for 2 min with subsequent washes with PBS for three times. After washing, sections were incubated with TUNEL reaction mixture with terminal deoxynucleotidyl transferase (TdT) at 37°C for 60 min under humidified condition, and nuclei were stained with DAPI. Negative controls were obtained by omitting the TdT enzyme. Images were captured by using a Nikon ECLIPSE Ti microscope and were analysed by using ImageJ software. Apoptotic cells were characterized by green fluorescence of the nucleus and nuclear membrane according to the manufacturer’s protocol. Quantitation was performed by counting the number of positive cells in five randomly chosen fields within each slide at 400× magnification. The index of
apoptosis was calculated as the ratio of the overall number of apoptotic cells to the total number of cells.

**Immunofluorescence staining**

Brain sections obtained at 24 h after HI were incubated with 5% BSA at 37°C for 30 min in PBS. Sections were then incubated with the appropriate primary antibody overnight at 4°C in the same buffer. Nuclei were stained with DAPI for 5 min at room temperature and mounted with Mowiol [24, 25]. For ER stress detection, brain sections were prepared as previously described, and primary antibodies against GRP78 (1:500, Abcam) and PDI (1:500, Abcam) were used. After primary antibody incubation, sections were washed and then incubated for 1 h with the appropriate secondary antibody (1:1000; Invitrogen Corporation, Carlsbad, CA, USA) [26]. Images were captured by using a Nikon ECLIPSE Ti microscope at 600× magnification and were analysed by using ImageJ software.

**Western blot analysis**

PC12 cells were lysed in protein extraction reagent with protease and phosphatase inhibitors. For in vivo studies, animals were eutha-
nized at 24 h after hypoxia and were subjected to perfusion with ice-cold 0.9% NaCl after decapitation. Total proteins were isolated from the hippocampus using mammalian tissue extraction reagent according to the manufacturer’s protocol. An equal amount of protein was fractionated by 12% SDS-PAGE and transferred onto a PVDF membrane (Bio-Rad, Hercules, CA). Membranes were blocked with 5% skim milk for 1.5 h at room temperature and were subsequently incubated with the primary antibodies, including GRP78 (1:1000), ATF6 (1:1000), PDI (1:1000), ATF4 (1:1000), XBP-1 (1:1000), CHOP (1:300), caspase12 (1:1000) and caspase3 (1:1000) at 4°C overnight. In the following day, membranes were washed with TBST for 3 times and incubated with appropriate HRP-conjugated secondary antibodies at room temperature for 1 h [29, 30]. Proteins were detected by the ChemiDocTM XRS+ Imaging System (BioRad) and signal intensities were densitometrically quantified by Image J software (National Institutes of Health, Bethesda, MD, USA).

Statistical analysis

Data are expressed as the mean ± SEM from three independent experiments. Statistical significance was determined using Student’s t-test if comparing only two experimental groups or one-way ANOVA followed by Dunnett’s post hoc tests if analysing more than two groups. Differences were considered to be statistically significant when $P<0.05$.

Results

bFGF-induced brain recovery is associated with increased neuronal survival after HI brain injury in rats

We first examined whether treatment of bFGF protected against neonatal HI-induced brain
bFGF attenuates neonatal hypoxic-ischaemic brain injury

injury in vivo. bFGF was administered immediately after hypoxia, and the severity of brain injury was determined at 24 h after HI by evaluating the infarct volume via TTC staining. Treatment of bFGF significantly attenuated post-HI brain infarction, reducing the infarct volume by 13% in bFGF-treated HI animals as compared to their vehicle-treated HI littermates (P<0.05, Figure 1A, 1B). While extensive tissue damages in the ipsilateral cerebral cortex and hippocampus were noticed in the HI group 7 days after brain injury, no observable tissue injury was found in contralateral cerebral tissue. When compared with the HI group, treatment of bFGF significantly reduced necrosis, nuclear pyknosis and fragmentation, and infiltration of polymorphonuclear leukocytes and macrophages, which mediated a neuroprotective effect against brain injury in neonatal rats (Figure 1C).

Previous studies had shown that HI-induced brain injury was associated with an extensive neuronal death occurred in different areas of the brain, such as the cortex and hippocampus [31, 32]. We showed that bFGF attenuated brain infarction after HI injury, thus we postulated that such protective effect was attributed to reduced neuronal loss. Nissl staining was used to study morphology and pathology changes of neuronal tissue. It showed that healthy neurons which were characterized by round, pale-stained nuclei with scattered Nissl-stained bodies were throughout the cerebral cortex and hippocampus in the sham group. However, HI injury induced pyramidal neuron death in the cerebral cortex and hippocampus CA1 regions 7 d after injury, which was significantly reduced by bFGF treatment (Figure 2A). These findings suggest that bFGF administration protects neuronal survival and mediates tissue recovery in the brain after HI-induced injury.

Treatment of bFGF attenuates neuronal cell death after HI-induced brain injury in rats

Neuronal cell apoptosis was quantified by TUNEL staining. As shown in Figure 3A, increased
TUNEL-positive neuronal cell were detected in the ipsilateral cerebral cortex at 7 d post-HI brain injury in neonatal rats as compared with the sham group (P<0.05). bFGF administration significantly decreased TUNEL-positive cells in the brain sections of the bFGF-treated HI group (P<0.05). Increased neuronal apoptosis was further corroborated by western blotting analyses and showed that the protein level of cleaved caspase3 was decreased significantly in the bFGF-treated group as compared with the HI group treated with vehicle (Figure 3B). Our data support that bFGF administration reduces neuronal apoptosis and decreases the activation of caspase 3 protein.

Treatment of bFGF inhibits ER stress-related protein expression in neonatal rats after HI-induced brain injury

Based on the results obtained from aforementioned results and previous studies, we hypothesized that the neuroprotective effects of bFGF were mediated by inhibition of ER stress. We measured ER stress proteins by western blotting and immunofluorescence staining. Our
results indicated that protein levels of ATF-6, GRP-78, XBP-1, ATF-4, CHOP and cleaved caspase12 were significantly up-regulated in the brains of HI rats. However, bFGF treatment markedly decreased expression of these proteins suggesting the ER stress was down-regulated in the HI rat brains (Figure 4C). These findings were consistent with immunofluorescence results which demonstrated that abundant GRP78-positive and PDI-positive cells were observed in the cortex of vehicle-treated HI rats, while significantly reduced GRP78 and PDI staining was found in the same regions of the brain sections from bFGF-treated rats (Figures 4A, 5A). These results demonstrate that bFGF effectively attenuates the ER stress in neonatal rats after HI injury.

*Intranasal bFGF treatment preserves the brain structure in neonatal rats after HI-induced brain injury*

We showed that bFGF provided short-term (1 day) protection against HI brain injury in neonatal rats. To examine whether bFGF treatment improve long-term outcomes in neonatal rats after HI-induced brain injury, the brain structure was studied at 7 d post-HI injury. Severe degree of brain atrophy and subsequent loss of brain mass were occurred in the left cerebral hemisphere in neonatal rats at 7 d after HI (Figure 6A). Interestingly, intranasal administration of bFGF twice a day for 7 consecutive days significantly reversed these injuries. Our immunohistochemical staining also revealed that MAP-2, a biomarker of neuronal damage or grey matter injury, and MBP, a measure of oligodendrocyte loss or white matter injury, were rarely found in the brain of HI group, but intranasal administration of bFGF significantly reduced neuronal loss (vehicle group 53±10.7 vs. bFGF group 26±11.1, P<0.05) and oligodendrocyte loss (vehicle group 50±9.7 vs. bFGF group 27±10.8, P<0.05) at 7 d after HI. Taken together, these results demonstrate potent neuroprotective effects of bFGF and it could be used to treat HI injury in rats.

*Treatment of bFGF reduces oxygen-glucose deprivation (OGD)-induced cell death and ER stress in PC12 cells*

TUNEL assay was used to characterize cell death in OGD-treated PC12 cells. As shown in
bFGF attenuates neonatal hypoxic-ischaemic brain injury

Figure 7A, there were few apoptosis-positive cells in the sham group, but the number of apoptotic cells was markedly increased after 24 h of the OGD challenge. Less TUNEL-positive PC12 cells in the OGD+bFGF group suggested that bFGF reduced cell death in vitro. Furthermore, protein level of cleaved caspase3 decreased significantly in the bFGF-treated group when compared with the OGD group (Figure 7B). To further investigate whether bFGF mitigated the ER stress in PC12 cells, the ER stress proteins were measured via western blot analyses in PC12 cells at 24 h after OGD stimulation. As expected, protein levels of GRP78, CHOP, ATF-4 and PDI were significantly higher in the OGD group as compared to the control group. Moreover, treatment of bFGF can effectively down-regulated these ER stress-related protein levels (Figure 8). Taken together, our data suggest that the protective effects of bFGF may involve inhibition of ER stress-related proteins.

Discussion

Neonatal HI brain injury is a leading cause of morbidity and mortality. Current therapeutic options for this disease are rather limited, as many drugs have disappointed us in human trials although they were shown to be effective in preclinical animal studies. In this study, we sought to demonstrate that intranasal bFGF is a promising therapeutic strategy to protect against HI-induced brain injury in neonatal rats, which may provide further insight in developing an effective therapeutic approach treating neonatal HI brain injury in humans. One of the biggest hurdles is that most systemic medications do not cross the blood-brain barrier (BBB) to the CNS. Nevertheless, intranasal administration has emerged as a non-invasive alternative route for drug delivery into the CNS [34-36], and clinical trials incorporating this method have shown encouraging results [37]. Specifically, intranasal drug delivery allows rapid distribution of molecules to the CNS via bulk flow through the olfactory and trigeminal perivascular channels and slower delivery via olfactory bulb axonal transport. Olfactory neurons are the only first-order receptor cells with specialized processes that are directly exposed in the upper nasal passage, while the other parts of the neurons project to the olfactory bulb [38].
bFGF attenuates neonatal hypoxic-ischaemic brain injury

Moreover, drug molecules are transported into olfactory neurons via endocytosis and are further delivered to the olfactory epithelium via extracellular flow through intercellular clefts. Drug molecules reached the olfactory epithelium effectively diffuse into the subarachnoid space [33]. In the present study, we clearly demonstrate, for the first time, that intranasal treatment of bFGF attenuates neonatal HI brain damage, which leads to improved neurological outcomes in neonatal rats.

HI is one of the major pathological factors causing neonatal brain injury, which leads to neurodegeneration and neuronal cell death as a result. In developing brain, the cerebral cortex and the hippocampal CA1 and CA3 subregions in particular, is vulnerable to insults mediated by HI [39, 40]. Previous studies have shown that extensive neuronal cell apoptosis is found in the brain of newborn with HI brain injury, suggesting that cell apoptosis may be the mechanism underlying the onset of neurological disabilities associated with HI [41, 42]. Several lines of evidence reinforces the finding of neuronal cell apoptosis triggers subsequent brain dysfunctions in the early phase of HI brain injury and its detrimental effects could last for days or even weeks [43]. Nevertheless, the extent of neuronal cell death in neonatal death associated with HI brain injury remains unclear [44-46]. In this study, our results clearly indicated that treatment of bFGF significantly decreases the number of TUNEL-positive cells induced by HI, suggesting that bFGF improves neuronal cell death in the cortical and hippocampal subregions of the neonatal rats after HI brain injury.

The ER stress pathway, also known as the UPR, is a defensive cellular response characterized by the accumulation of unfolded proteins in the ER to preserve organelle function. The UPR pathway can be activated by various cellular stress processes and triggers programmed cell death [47]. Previous studies have shown that activation of the UPR pathway is commonly observed in neurodegenerative diseases relat-

Figure 7. bFGF inhibits apoptosis induced by OGD in PC12 cells. A. Detection of apoptotic cells by TUNEL (green) and DAPI (blue) staining assay. Bright green dots were deemed apoptosis-positive cells. B. Protein expression of cleaved caspase3 in the sham, OGD and bFGF-treated group. C. Optical density analysis of cleaved caspase3 protein. *represents P<0.01 versus the sham group, and #represents P<0.05 versus the OGD group. D. Analysis of apoptosis in the sham, OGD and bFGF-treated group. *represents P<0.01 versus the sham group, and #represents P<0.01 versus the OGD group. All data represent the mean value ± SEM, n=4.
bFGF attenuates neonatal hypoxic-ischaemic brain injury

ed to ageing, such as Alzheimer’s disease, Parkinson’s disease, or diabetes and cardiovascular diseases. Furthermore, the UPR pathway also plays a major role in the acute symptoms associated with ischemia or exposure to hypoxic conditions [48]. In our study, we examined whether treatment of bFGF mitigates the ER stress, which in turn inhibits the UPR pathway in neonatal rats after HI brain injury. GRP78 is an ER chaperone representing an indicator of ER stress [49]. PDI presents within the lumen of the ER, is known to catalyse the post-translational protein modification. In the quiescent state, a scarce amount of neurons are expressing GRP78 and PDI. However, when exposed to the HI insult, up-regulation of GRP78 and PDI is observed in injured neurons [50]. In our study, we found that GRP78 and PDI expression was significantly increased in the cortical and hippocampal regions of the brain in neonatal rats at 24 h after HI injury. Intranasal treatment of bFGF decreased the levels of ER stress-related proteins and inhibited neuronal cell apoptosis. These results indicated that the protective role of bFGF in neonatal HI injury was related to suppression of ER stress. Further study was needed to determine whether inhibition of ER stress-induced apoptosis by bFGF also leads to reversal of the UPR pathway and subsequently reactivates innate immunity, metabolism and cell differentiation. Our results were consistent with previous studies suggesting that bFGF attenuated ER stress in different animal models of HI injury. For instance, treatment of bFGF inhibited ER stress induced by ischaemic oxidative injury via activation of the PI3K/Akt and ERK1/2 pathways [49]. Similar findings were also observed in others studies investigating myocardial ischaemia/reperfusion injury [51] and spinal cord injury [52]. Thus, it is conceivable that bFGF may play an important role in ER stress induced by neonatal HI injury.

bFGF is highly expressed in the nervous system where it has multiple roles and exogenous bFGF has been shown to have neuroprotective

**Figure 8.** bFGF inhibits OGD-induced ER stress in PC12 cells. A. The western blotting results for GRP78, CHOP, ATF-4, and PDI. B. Optical density analysis of GRP78. C. Optical density analysis of CHOP. D. Optical density analysis of PDI and ATF-4. ** represents \( P<0.01 \) versus the sham group, and # represents \( P<0.05 \) versus the OGD group. All data represent the mean value ± SEM, \( n=4 \).
bFGF attenuates neonatal hypoxic-ischaemic brain injury

function in brain injury. However, it is no doubt that the limitations of bFGF in HI injury therapy still need further investigations and improvements. For example, it is increasingly clear that exploiting a single pathophysiological pathway might not be sufficient to combat neonatal HI brain injury. Promising neuroprotective drugs should be studied in combination with hypothermia, because temperature change can greatly alter the pharmacokinetics and pharmacodynamics of various drugs. Moreover, bFGF has a short biological half-life due to the presence of degrading enzymes in vivo. Therefore, future work focuses on developing a delivery system that increases bFGF stability may bolster its therapeutic function for treating infants with HI brain injury.

Acknowledgements

This work was supported by the National Natural Science Foundation of China (NO. 81302775, 81472165, 81560375), The Zhejiang Provincial Program for the Cultivation of High-level Innovative Health Talents (to J.X.), and the Wenzhou Science and Technology Foundation (Y20140681). Science and technology project of Zhejiang Province (LY17H090017 to Z.W.).

Disclosure of conflict of interest

None.

Address correspondence to: Dr. Jian Xiao, Molecular Pharmacology Research Center, School of Pharmacy, Wenzhou Medical University, Wenzhou 325035, Zhejiang, China. E-mail: xfxj2000@126.com; Dr. Li Liu, Department of Neonatology, The First Affiliated Hospital of X’ian Jiaotong University, X’ian 710061, Shaanxi, China. E-mail: nelie91800@163.com

References

bFGF attenuates neonatal hypoxic-ischaemic brain injury


bFGF attenuates neonatal hypoxic-ischaemic brain injury


